Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0782
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    +0.0004 (+0.03%)
     
  • USD/JPY

    151.3460
    -0.0260 (-0.02%)
     
  • Bitcoin USD

    69,965.85
    -635.27 (-0.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Summary Box: Watson buying Actavis for $5.6B

Summary Box: Generic drugmaker Watson agrees to buy Actavis of Switzerland for $5.6B

THE DEAL: Watson Pharmaceuticals Inc. said Wednesday that it will buy Swiss drugmaker Actavis for $5.6 billion, forming the third-largest generic drug company in the world.

GROWING: Watson is currently the fourth-largest maker of generic drugs. It had expected about $5.4 billion in revenue this year while Actavis had $2.5 billion in revenue in 2011. The Parsippany, N.J., company said it expects the purchase to close during the fourth quarter of 2012.

OVERSEAS MARKETS: Watson CEO Paul Bisaro said the deal will boost Watson's position in Russia and Central and Eastern Europe, and complement its products in the U.S.

Advertisement